• 1
    American Cancer Society. Cancer Facts & Figures 2011. Atlanta: American Cancer Society, 2011
  • 2
    Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 V1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. Lyon, France: International Agency for Research on Cancer, 2010. Available at: Accessed September 2011
  • 3
    NCCN Clinical Practice Guidelines in Oncology™ Kidney Cancer. Version 2.2010. ©2009 National Comprehensive Cancer Network, Inc. Available at: Accessed September 2011
  • 4
    Howlader N, Noone AM, Krapcho M et al. SEER Cancer Statistics Review, 1975–2008. Bethesda: National Cancer Institute, 2011. Available at:, based on November 2010 SEER data submission, posted to the SEER web site. Accessed September 2011
  • 5
    Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet 2009; 373: 111932
  • 6
    Rini BI, Atkins MB. Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol 2009; 10: 9921000
  • 7
    Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999; 17: 253040
  • 8
    Négrier S, Escudier B, Gomez F et al. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie. Ann Oncol 2002; 13: 14608
  • 9
    Heng DY, Xie W, Regan MM et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009; 27: 57949
  • 10
    Mekhail TM, Abou-Jawde RM, Boumerhi G et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 2005; 23: 83241
  • 11
    Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 12534
  • 12
    Escudier B, Roigas J, Gillessen S et al. Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. J Clin Oncol 2009; 27: 406875
  • 13
    Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 20516
  • 14
    Jagannath S, Velasquez WS, Tucker SL et al. Tumor burden assessment and its implication for a prognostic model in advanced diffuse large-cell lymphoma. J Clin Oncol 1986; 4: 85965
  • 15
    Gobbi PG, Valentino F, Bassi E et al. Chemoresistance as a function of the pretherapy tumor burden and the chemotherapy regimen administered: differences observed with 2 current chemotherapy regimens for advanced Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk 2011; 11: 396402
  • 16
    Illidge TM, Bayne M, Brown NS et al. Phase 1/2 study of fractionated (131)I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy. Blood 2009; 113: 141221
  • 17
    Caudle AS, Gonzalez-Angulo AM, Hunt KK et al. Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2010; 28: 18218
  • 18
    Song MK, Chung JS, Shin HJ et al. Clinical significance of metabolic tumor volume by PET/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvement. Ann Hematol 2012; 91: 697703
  • 19
    Liao S, Penney BC, Zhang H, Suzuki K, Pu Y. Prognostic value of the quantitative metabolic volumetric measurement on 18F-FDG PET/CT in Stage IV nonsurgical small-cell lung cancer. Acad Radiol 2012; 19: 6977
  • 20
    Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. Solid renal tumors: an analysis of pathological features related to tumor size. J Urol 2003; 170: 221720
  • 21
    Thompson RH, Kurta JM, Kaag M et al. Tumor size is associated with malignant potential in renal cell carcinoma cases. J Urol 2009; 181: 20336
  • 22
    Zisman A, Pantuck AJ, Wieder J et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol 2002; 20: 455966
  • 23
    Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol 2002; 168: 2395400
  • 24
    Stein WD, Huang H, Menefee M et al. Other paradigms: growth rate constants and tumor burden determined using computed tomography data correlate strongly with the overall survival of patients with renal cell carcinoma. Cancer J 2009; 15: 4417
  • 25
    Abraham J, Agrawal M, Bakke S et al. Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days. J Clin Oncol 2003; 21: 186673
  • 26
    Huang H, Menefee M, Edgerly M et al. A phase II clinical trial of ixabepilone (Ixempra; BMS-247550; NSC 710428), an epothilone B analog, in patients with metastatic renal cell carcinoma. Clin Cancer Res 2010; 16: 163441
  • 27
    Basappa NS, Elson P, Golshayan AR et al. The impact of tumor burden characteristics in patients with metastatic renal cell carcinoma treated with sunitinib. Cancer 2011; 117: 11839
  • 28
    Seidel C, Fenner M, Reuter C, Merseburger AS, Ganser A, Grünwald V. Retrospective analyses of patient characteristics having predictive impact on survival under everolimus. Onkologie 2011; 34: 1114
  • 29
    Escudier B, Eisen T, Stadler WM et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009; 27: 33128
  • 30
    Motzer RJ, Escudier B, Oudard S et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010; 116: 425665
  • 31
    Yuasa T, Urakami S, Yamamoto S et al. Tumor size is a potential predictor of response to tyrosine kinase inhibitors in renal cell cancer. Urology 2011; 77: 8315
  • 32
    Bex A, Blank C, Meinhardt W, van Tinteren H, Horenblas S, Haanen J. A phase II study of presurgical sunitinib in patients with metastatic clear-cell renal carcinoma and the primary tumor in situ. Urology 2011; 78: 8327
  • 33
    Thiam R, Fournier LS, Trinquart L et al. Optimizing the size variation threshold for the CT evaluation of response in metastatic renal cell carcinoma treated with sunitinib. Ann Oncol 2010; 21: 93641
  • 34
    Krajewski KM, Guo M, Van den Abbeele AD et al. Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma. Eur Urol 2011; 59: 85662
  • 35
    National Comprehensive Cancer Network (NCCN) guideline for kidney cancer. Available at: Accessed September 2011